Scarica l'app Stockscreener
2.29
1.29%
-0.03
Precedente Chiudi:
$2.32
Aprire:
$2.34
Volume 24 ore:
5.29M
Relative Volume:
1.19
Capitalizzazione di mercato:
$530.03M
Reddito:
-
Utile/perdita netta:
$-179.82M
Rapporto P/E:
-1.7218
EPS:
-1.33
Flusso di cassa netto:
$-159.16M
1 W Prestazione:
+1.33%
1M Prestazione:
-13.91%
6M Prestazione:
+16.24%
1 anno Prestazione:
+74.81%
Intervallo 1D:
$2.28
$2.495
Intervallo di 1 settimana:
$2.16
$2.495
Portata 52W:
$0.76
$3.87
Gossamer Bio Inc Stock (GOSS) Company Profile
Nome
Gossamer Bio Inc
Settore
Industria
Telefono
(858) 684-1300
Indirizzo
3115 MERRYFIELD ROW, SAN DIEGO, CA
Compare GOSS vs VRTX, REGN, ARGX, ALNY, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
GOSS
Gossamer Bio Inc
|
2.29 | 536.98M | 0 | -179.82M | -159.16M | -1.33 |
|
VRTX
Vertex Pharmaceuticals Inc
|
491.47 | 117.98B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
803.17 | 82.85B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
821.96 | 51.58B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
314.40 | 40.75B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
346.07 | 38.33B | 4.98B | 69.60M | 525.67M | 0.5198 |
Gossamer Bio Inc Stock (GOSS) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-01-28 | Iniziato | Barclays | Overweight |
| 2025-09-10 | Aggiornamento | UBS | Neutral → Buy |
| 2025-07-14 | Iniziato | Scotiabank | Sector Outperform |
| 2024-06-25 | Iniziato | Oppenheimer | Outperform |
| 2024-04-05 | Ripresa | Wedbush | Outperform |
| 2023-07-27 | Downgrade | UBS | Buy → Neutral |
| 2023-03-07 | Downgrade | Raymond James | Outperform → Mkt Perform |
| 2023-03-01 | Iniziato | Guggenheim | Neutral |
| 2022-12-07 | Downgrade | Barclays | Overweight → Equal Weight |
| 2022-12-07 | Downgrade | JP Morgan | Neutral → Underweight |
| 2022-12-07 | Downgrade | SMBC Nikko | Outperform → Neutral |
| 2022-10-20 | Iniziato | Goldman | Buy |
| 2022-09-21 | Iniziato | JP Morgan | Neutral |
| 2022-09-19 | Iniziato | Wedbush | Outperform |
| 2022-04-18 | Iniziato | Raymond James | Outperform |
| 2022-04-06 | Iniziato | UBS | Buy |
| 2022-01-10 | Aggiornamento | SMBC Nikko | Neutral → Outperform |
| 2021-11-09 | Ripresa | Cantor Fitzgerald | Overweight |
| 2021-09-21 | Ripresa | Piper Sandler | Overweight |
| 2020-06-29 | Iniziato | H.C. Wainwright | Buy |
| 2020-04-22 | Iniziato | Piper Sandler | Overweight |
| 2020-02-27 | Iniziato | Barclays | Overweight |
| 2019-12-03 | Ripresa | BofA/Merrill | Buy |
| 2019-10-30 | Iniziato | Berenberg | Buy |
| 2019-03-05 | Iniziato | Barclays | Overweight |
| 2019-03-05 | Iniziato | BofA/Merrill | Buy |
| 2019-03-05 | Iniziato | Evercore ISI | Outperform |
| 2019-03-05 | Iniziato | SVB Leerink | Outperform |
Mostra tutto
Gossamer Bio Inc Borsa (GOSS) Ultime notizie
Gossamer Bio’s Stock Whipsaws As Biotech Investors Weigh Risk, Cash Runway And Pipeline Hopes - AD HOC NEWS
Brokers Offer Predictions for Gossamer Bio FY2030 Earnings - MarketBeat
Big Money Bets On Gossamer Bio (GOSS) As Institutional Ownership Hits 81 Percent - AOL.com
MB Generational Wealth LLC Buys Shares of 1,414,824 Gossamer Bio, Inc. $GOSS - MarketBeat
Gossamer Bio (NASDAQ:GOSS) Trading Down 4.7%Here's What Happened - MarketBeat
Analysts Remain Bullish on Gossamer Bio (GOSS) Citing Undervaluation - Insider Monkey
11 Best Stocks Under $3 to Buy Right Now - Insider Monkey
Gossamer Bio Target of Unusually High Options Trading (NASDAQ:GOSS) - Defense World
Analysts Have Conflicting Sentiments on These Healthcare Companies: Minerva Neurosciences (NERV), Gossamer Bio (GOSS) and Merck & Company (MRK) - The Globe and Mail
Gossamer Bio, Inc. (GOSS): Biotech Stock With A Promising 283% Upside Potential - DirectorsTalk Interviews
Traders Buy High Volume of Gossamer Bio Put Options (NASDAQ:GOSS) - MarketBeat
Gossamer Bio (NASDAQ:GOSS) Shares Up 8.8%Should You Buy? - MarketBeat
Barclays Gives Gossamer Bio Overweight Rating and Bright Outlook - StocksToTrade
Gossamer Bio Sees Unusually Large Options Volume (NASDAQ:GOSS) - MarketBeat
Gossamer Bio (NASDAQ:GOSS): The High-Stakes Gamble Drawing Big Bank Interest - AOL.com
Is Gossamer Bio Inc forming a breakout pattern2025 Price Action Summary & Weekly Sector Rotation Insights - baoquankhu1.vn
Gossamer Bio (NASDAQ:GOSS) Upgraded to "Strong-Buy" at Barclays - MarketBeat
Gossamer Bio (GOSS) Submits Mixed Securities Shelf Filing - GuruFocus
Barclays Initiates Coverage on Gossamer Bio With Overweight Rating, $9 Price Target - marketscreener.com
Barclays Initiates Coverage on Gossamer Bio (GOSS) with Overweig - GuruFocus
Institution Moves: Should I buy Gossamer Bio Inc stock nowTrade Signal Summary & Daily Stock Trend Watchlist - baoquankhu1.vn
Earnings Report: Is Gossamer Bio Inc a stock for growth or value investors2025 Performance Recap & Smart Swing Trading Alerts - baoquankhu1.vn
Gossamer Bio (NASDAQ:GOSS) Rating Lowered to Sell at Wall Street Zen - MarketBeat
Gossamer Bio (NASDAQ:GOSS) Stock Price Down 5.7%Here's Why - MarketBeat
Cantor Fitzgerald reiterates Overweight rating on Gossamer Bio stock By Investing.com - Investing.com Nigeria
H.C. Wainwright reiterates Buy rating on Gossamer Bio stock ahead of key trial By Investing.com - Investing.com India
Cantor Fitzgerald reiterates Overweight rating on Gossamer Bio stock - Investing.com
H.C. Wainwright reiterates Buy rating on Gossamer Bio stock ahead of key trial - Investing.com Nigeria
Gossamer Bio (NASDAQ:GOSS) Given Buy Rating at HC Wainwright - MarketBeat
GOSS: HC Wainwright & Co. Reiterates Buy Rating with $10 Price T - GuruFocus
With 63% institutional ownership, Gossamer Bio, Inc. (NASDAQ:GOSS) is a favorite amongst the big guns - Yahoo Finance
Gossamer Bio, Inc.'s (NASDAQ:GOSS) Popularity With Investors Under Threat As Stock Sinks 27% - simplywall.st
Gossamer Bio Inc Just Went Wild: Is This Tiny Biotech the Next Viral Moonshot or Total Trap? - AD HOC NEWS
Aug Spikes: How does Napco Security Technologies Inc score in quality rankingsTrade Volume Summary & Safe Capital Allocation Plans - baoquankhu1.vn
Pullback Watch: What are the risks of holding ProShares Trust ProShares Short MSCI Emerging MarketsWeekly Market Summary & Expert Approved Trade Ideas - baoquankhu1.vn
Gossamer Bio, Inc. (NASDAQ:GOSS) Given Average Recommendation of "Moderate Buy" by Analysts - MarketBeat
What is the fair value of Gossamer Bio Inc. stock nowTrade Exit Summary & Smart Investment Allocation Tips - Улправда
Is Gossamer Bio Inc. stock trading at a premium valuation2025 Winners & Losers & High Accuracy Investment Signals - Улправда
Gossamer Bio, Inc. (GOSS): Analyst Ratings Highlight a Significant 294% Upside for Biotech Investors - DirectorsTalk Interviews
How Gossamer Bio Inc. (4GB) stock reacts to stronger dollarTrade Analysis Report & AI Powered Market Entry Ideas - Улправда
Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - MarketScreener
Biotech Gossamer Bio gives new hires a stake with long-term stock options - Stock Titan
Can Gossamer Bio Inc. stock hit record highs againJuly 2025 Macro Moves & Weekly Setup with High ROI Potential - Улправда
Gossamer Bio Sees Unusually High Options Volume (NASDAQ:GOSS) - Defense World
Gossamer Bio Currently Down Eight Consecutive Days, on Pace for Longest Losing Streak Since November 2024 -- Data Talk - 富途牛牛
Gossamer Bio Inc Azioni (GOSS) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.12%
0.87%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):